AirLeaf - Bronchiectasis Clinical Trial

The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis.

Category

<a class="catlink" href="/clinical-trials?cat=respiratory_infectiousdiseaseandoncology">Respiratory, Infectious Disease and Oncology</a>

Trial Status

Recruiting

Trial Phase

Phase 2 Drug Trial

Registry Listing

Trial contact details

Contact Person

RIO Clinical Trials Team

Phone

What you need to know

This study is open to adults (≥18 and ≤85 years) with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations).
History of pulmonary exacerbations requiring antibiotic treatment in the past 12 months

Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day.
Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff.
The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.

October 2022 to October 2023